{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T17:16:07Z","timestamp":1765041367844,"version":"3.37.3"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2023,4,15]],"date-time":"2023-04-15T00:00:00Z","timestamp":1681516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,19]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>Interstitial lung disease (ILD) is a common extra-articular manifestation of rheumatoid arthritis (RA). Nintedanib has been approved for the treatment of idiopathic pulmonary fibrosis. Herein, we described the case of an 87-year-old woman treated with Janus kinase inhibitor (JAKi). Chest computed tomography revealed increased honeycombing; she was administered nintedanib while continuing RA treatment. The combination treatment (JAKi and nintedanib) controlled the RA disease activity without ILD deterioration. This case shows the potential of combination treatment with JAKi and nintedanib for the prevention of worsening of disease activity in RA and ILD.<\/jats:p>","DOI":"10.1093\/mrcr\/rxad021","type":"journal-article","created":{"date-parts":[[2023,4,16]],"date-time":"2023-04-16T07:16:19Z","timestamp":1681629379000},"page":"350-353","source":"Crossref","is-referenced-by-count":5,"title":["Combination treatment with Janus kinase inhibitor and nintedanib for rheumatoid arthritis with progressive interstitial lung disease: A case report"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8316-8671","authenticated-orcid":false,"given":"Takeshi","family":"Mochizuki","sequence":"first","affiliation":[{"name":"Department of Orthopaedic Surgery and Rheumatology, Kamagaya General Hospital , Chiba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichiro","family":"Yano","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Tokyo Women\u2019s Medical University , Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsunori","family":"Ikari","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Tokyo Women\u2019s Medical University , Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Okazaki","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Tokyo Women\u2019s Medical University , Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,4,15]]},"reference":[{"key":"2023072617541089800_R1","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000017088","article-title":"High-resolution computed tomography of the lung in patients with rheumatoid arthritis: prevalence of interstitial lung disease involvement and determinants of abnormalities","volume":"98","author":"Salaffi","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"2023072617541089800_R2","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1007\/s12325-020-01578-6","article-title":"Estimation of the prevalence of progressive fibrosing interstitial lung diseases: systematic literature review and data from a physician survey","volume":"38","author":"Olson","year":"2021","journal-title":"Adv Ther"},{"key":"2023072617541089800_R3","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.resinv.2021.04.011","article-title":"2020 Guide for the diagnosis and treatment of interstitial lung disease associated with connective tissue disease","volume":"59","author":"Kondoh","year":"2021","journal-title":"Respir Investig"},{"key":"2023072617541089800_R4","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0076-2018","article-title":"Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases","volume":"27","author":"Cottin","year":"2018","journal-title":"Eur Respir Rev"},{"key":"2023072617541089800_R5","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2021.106574","article-title":"Efficacy and safety of nintedanib in Japanese patients with progressive fibrosing interstitial lung diseases: subgroup analysis of the randomised, double-blind, placebo-controlled, phase 3 INBUILD trial","volume":"187","author":"Inoue","year":"2021","journal-title":"Respir Med"},{"key":"2023072617541089800_R6","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N Engl J Med"},{"key":"2023072617541089800_R7","first-page":"41","article-title":"Management of rheumatoid arthritis patients with interstitial lung disease: safety of biological antirheumatic drugs and assessment of pulmonary fibrosis","volume":"9","author":"Mori","year":"2015","journal-title":"Clin Med Insights Circ Respir Pulm Med"},{"key":"2023072617541089800_R8","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1093\/rheumatology\/key208","article-title":"The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis","volume":"58","author":"Holroyd","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2023072617541089800_R9","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s10787-022-00936-w","article-title":"A retrospective study of the efficacy of JAK inhibitors or abatacept on rheumatoid arthritis-interstitial lung disease","volume":"30","author":"Tardella","year":"2022","journal-title":"Inflammopharmacology"},{"key":"2023072617541089800_R10","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/25785826.2021.1928383","article-title":"Prevalence and predictive factors of difficult-to-treat rheumatoid arthritis: the KURAMA cohort","volume":"45","author":"Watanabe","year":"2022","journal-title":"Immunol Med"},{"key":"2023072617541089800_R11","doi-asserted-by":"crossref","first-page":"L998","DOI":"10.1152\/ajplung.00304.2017","article-title":"Nintedanib reduces pulmonary fibrosis in a model of rheumatoid arthritis-associated interstitial lung disease","volume":"314","author":"Redente","year":"2018","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"2023072617541089800_R12","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1002\/art.42075","article-title":"Nintedanib in patients with autoimmune disease-related progressive fibrosing interstitial lung diseases: subgroup analysis of the INBUILD trial","volume":"74","author":"Matteson","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2023072617541089800_R13","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-019-1835-9","article-title":"Serum KL-6 levels reflect the severity of interstitial lung disease associated with connective tissue disease","volume":"21","author":"Lee","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2023072617541089800_R14","doi-asserted-by":"crossref","first-page":"4705","DOI":"10.21037\/jtd.2018.07.76","article-title":"Sequential changes of serum KL-6 predict the progression of interstitial lung disease","volume":"10","author":"Jiang","year":"2018","journal-title":"J Thorac Dis"},{"key":"2023072617541089800_R15","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.2169\/internalmedicine.1890-18","article-title":"Remarkable improvement in a patient with idiopathic pulmonary fibrosis after treatment with nintedanib","volume":"58","author":"Nakano","year":"2019","journal-title":"Intern Med"},{"key":"2023072617541089800_R16","doi-asserted-by":"crossref","first-page":"528","DOI":"10.5603\/ARM.a2021.0072","article-title":"Nintedanib-mediated improvement in CT imaging in pulmonary fibrosis associated with systemic scleroderma","volume":"89","author":"Nishino","year":"2021","journal-title":"Adv Respir Med"}],"container-title":["Modern Rheumatology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mrcr\/advance-article-pdf\/doi\/10.1093\/mrcr\/rxad021\/50200219\/rxad021.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/7\/2\/350\/50967835\/rxad021.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/7\/2\/350\/50967835\/rxad021.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T18:07:23Z","timestamp":1690394843000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mrcr\/article\/7\/2\/350\/7123801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,15]]},"references-count":16,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,4,15]]},"published-print":{"date-parts":[[2023,6,19]]}},"URL":"https:\/\/doi.org\/10.1093\/mrcr\/rxad021","relation":{},"ISSN":["2472-5625"],"issn-type":[{"type":"electronic","value":"2472-5625"}],"subject":[],"published-other":{"date-parts":[[2023,7,1]]},"published":{"date-parts":[[2023,4,15]]}}}